Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed...
Ophthalmology
Arctic Vision and Santen Ink Deal for ARVN001 Commercialization in China
China-based ophthalmology specialist, Arctic Vision, has entered into a strategic collaboration with Japan’s Santen Pharmaceutical...
Boehringer Ingelheim Joins MTM Vision Consortium to Advance Diabetes Retinopathy Research
Germany-based pharmaceutical major Boehringer Ingelheim has announced the initiation of a long-term collaboration with the...
Frontera Therapeutics Receives FDA Approval for Phase II Study of FT-003 in nAMD
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...
China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...
Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...
Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...
LENZ Therapeutics’ Presbyopia Therapy LNZ100 Accepted for FDA Review
LENZ Therapeutics, Inc. (NASDAQ: LENZ), a US-based biopharmaceutical company, has announced that the US Food...
Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE
Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that...
United Laboratories’ TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced the...
Roche’s Vabysmo Receives NMPA Approval for Macular Edema Treatments in China
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the receipt of another marketing approval...
iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
iRegene Therapeutics, a Wuhan-based biotechnology company specializing in the development of AI-enhanced chemically induced cell...
Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
Reforgene Medicine, a pioneer in gene editing therapy based in Guangzhou, has secured Investigational New...
Novartis’s Brolucizumab Accepted for Review by China’s CDE for Potential DME Treatment
The Center for Drug Evaluation (CDE) has indicated that Novartis (NYSE: NVS), the Swiss pharmaceutical...
HOYA Surgical Optics Expands in China with New Artificial Intraocular Lens Facility
HOYA Surgical Optics has established its presence in the Suzhou High-Tech Zone of Jiangsu province,...
Amgen’s Tepezza Receives Approval in Japan for Treating Thyroid Eye Disease
Amgen (NASDAQ: AMGN), a prominent biotechnology company based in the U.S., has announced that its...
Frontera Therapeutics Receives FDA Approval for Phase II Study of First Chinese rAAV Gene Therapy
Frontera Therapeutics, Inc., a Sino-US biopharmaceutical company, has announced that it has received approval from...
Ocumension Therapeutics’ OT-502 Receives NMPA Acceptance for Post-Cataract Inflammation Treatment
Ocumension Therapeutics (HKG: 1477) announced on September 23, 2024, that the National Medical Products Administration...
Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...